Zobrazeno 1 - 9
of 9
pro vyhledávání: '"María del Pilar Briceño-Casado"'
Publikováno v:
Farmacia Hospitalaria, Vol 44, Iss 5, Pp 212-217 (2020)
Objective:New monoclonal antibodies against the calcitonin generelated peptide pathway have recently been developed for the prevention of migraine. The aim of this study is to compare the efficacy of monoclonal antibodies against the calcitonin gener
Externí odkaz:
https://doaj.org/article/87841b4ff0354df397f3633f39217623
Autor:
Silvia Fénix-Caballero, Manuel David Gil-Sierra, María Del Pilar Briceño-Casado, Marina Sánchez-Hidalgo, Catalina Alarcón de la Lastra-Romero, Emilio Jesús Alegre-Del Rey
Publikováno v:
Journal of Oncology Pharmacy Practice. 29:155-161
Introduction There is subgroup analysis suggesting a lack of benefit of daratumumab use in multiple myeloma (MM) and hepatic disease (HD). The objectives of this study were to conduct a systematic review and interpretation of daratumumab-based regime
Publikováno v:
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 46(6)
Patient empowerment is one of the main pillars of humanisation. Therefore, consideration of patients' preferences and expectations should be taken into account during the practice of any healthcare professional. Improving overall survival and quality
Autor:
Manuel David, Gil-Sierra, María Del Pilar, Briceño-Casado, Ángel Jesús, Arias-Arias, Santiago, Martín-Rodríguez
Publikováno v:
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 46(3)
The European Medicines Agency's marketing authorisation criteria for drugs are reflected in the European Public Assessment Reports. The objective is to describe the expectations and preferences of our oncohematological outpatients with respect to the
Autor:
Ester María, Barreiro-Fernández, Manuel David, Gil-Sierra, María Del Pilar, Briceño-Casado, Carmen, Martínez-Díaz, Esmeralda, Ríos-Sánchez
Publikováno v:
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 46(3)
Publikováno v:
JAMA oncology. 8(4)
Publikováno v:
Farmacia Hospitalaria v.44 n.5 2020
SciELO España: Revistas Científicas Españolas de Ciencias de la Salud
Instituto de Salud Carlos III (ISCIII)
SciELO España. Revistas Científicas Españolas de Ciencias de la Salud
instname
Farmacia Hospitalaria, Vol 44, Iss 5, Pp 218-221 (2020)
SciELO España: Revistas Científicas Españolas de Ciencias de la Salud
Instituto de Salud Carlos III (ISCIII)
SciELO España. Revistas Científicas Españolas de Ciencias de la Salud
instname
Farmacia Hospitalaria, Vol 44, Iss 5, Pp 218-221 (2020)
Ustekinumab is used in moderate-severe plaque psoriasis with inadequate response to anti-tumour necrosis factor α drugs. Recent studies support the need to assess real long-term data. The aim of this study was to evaluate the real long-term effectiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::8dc871e05f5770bf108d7c6d1a22517f
http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-63432020000500005
http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-63432020000500005
Publikováno v:
European Journal of Hospital Pharmacy. :ejhpharm-2021
A multicentre case series of patients with chronic migraine (CM) treated with monoclonal antibodies directed against calcitonin gene-related peptide (CGRP-mAbs) switching were developed. The effectiveness and safety of CGRP-mAbs switching as a preven
Publikováno v:
JAMA Oncology. 6:1122